摘要
心脏是一个非常重要的器官,并且心血管紊乱在生活中是威胁生命的主要疾病。心血管蛋白中异常的蛋白质翻译后修饰(PTMs)与心脏病理性异常非常相关。SUMO化修饰作为最受欢迎的PTMs之一,细胞中有着成千上万的基板,也在心脏研究中表现出能够精准的控制细胞的存活和繁殖,能够针对性地控制线粒体和肌浆网生理心脏功能的作用。万幸的是病理心脏SUMO修饰化被视为心血管疾病的干预和治疗目标。因此,本文对近年来心脏方面SUMO化修饰通路的功能进行了综述。尤其讨论了心血管发育和包括心肌线粒体功能、心肌收缩力、稳态应力适应和蛋白质的心血管健康SUMO化修饰或解离的生物学意义。我们还讨论了SUMO化修饰等翻译后修饰的的乙酰化和泛素化之间的关系。这些关系不仅为我们对心血管紊乱调整机制的知识增进了理解,也对未来治疗作出了贡献。
关键词: SUMO化修饰,线粒体,肌内质网Ca2+-atp酶,组蛋白去乙酰化酶,心衰
Current Molecular Medicine
Title:Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Volume: 16 Issue: 10
关键词: SUMO化修饰,线粒体,肌内质网Ca2+-atp酶,组蛋白去乙酰化酶,心衰
摘要: Heart is an extremely important organ, and cardiovascular disorders emerge as primary life-threatening disease in human life. Aberrant post-translational modifications (PTMs) on cardiac proteins are closely correlated with pathological abnormalities in heart. SUMOylation, one of the most prevalent PTMs with thousands of substrates throughout the cell including critical subcellular organelles, has been shown to precisely finetune the cell survival and proliferation during heart development, and delicately control the function of mitochondrion and sarcoplasmic reticulum in physiological heart functioning. The silver lining is pathologically cardiacspecific SUMOylation being considered as target for cardiovascular disease intervention and treatment. Here, we summarize the recent progress in heart-specific functions of the SUMOylation pathway. In particular, we discuss the biological significance of SUMO conjugation/deconjugation during heart development, and in physiological cardiovascular health involving cardiac mitochondrial function, cardiac contractility, stress adaption and protein homeostasis. We also discuss the crosstalks between sumoylation and other post-translational modifications such as acetylation and ubiquitination. These crosstalks not only shed light to our understanding of the regulatory mechanisms on cardiovascular disorders but also contributes to their future therapy.
Export Options
About this article
Cite this article as:
Roles of SUMOylation in Heart Development and Cardiovascular Diseases, Current Molecular Medicine 2016; 16 (10) . https://dx.doi.org/10.2174/1566524016666161223110407
DOI https://dx.doi.org/10.2174/1566524016666161223110407 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Comparison of Granulomatosis with Polyangiitis Clinical Features in Patients Depending on Involvement or Absence of Kidney Involvement
Current Rheumatology Reviews Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism The Pharmacology of Diabetic Complications
Current Medicinal Chemistry Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Apelin in the Control of Body Fluid Homeostasis and Cardiovascular Functions
Current Pharmaceutical Design By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon
Current Vascular Pharmacology Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
Recent Patents on Anti-Infective Drug Discovery